New Probe Detects Fusion of bcr/abl
DOWNERS GROVE, Ill--Vysis Inc. has announced the availability of the Locus Specific Identifier (LSITM) bcr/abl translocation probe, a dual-color probe mixture that detects gene fusion of the bcr and abl genes.
DOWNERS GROVE, Ill--Vysis Inc. has announced the availabilityof the Locus Specific Identifier (LSITM) bcr/abl translocationprobe, a dual-color probe mixture that detects gene fusion ofthe bcr and abl genes.
This translocation has been associated with chronic myelogenousleukemia (CML) and acute lymphocytic leukemia (ALL).
The new probe, which is for research use only, is based on proprietaryapplications of FISH (fluorescence in situ hybridization) technology.The probe directly detects target DNA by hybridizing to specificlocations on individual chromosomes, the company said.
Bright Fluorescent Signal
Following hybridization, a bright fluorescent signal is emittedthat can be observed with use of a fluorescence microscope andimaging systems (see figure).
The LSI bcr/abl probe consists of a single probe for bcr (breakpointcluster region), directly labeled with the SpectrumGreenTM fluorochrome,and another probe for the Abelson oncogene (c-abl), directly labeledwith the Spec- trumOrangeTM fluorochrome.
The assay allows the user to quantitatively evaluate both probessimultaneously, either in interphase nuclei or metaphase cells.
![A third of patients had a response [to lifileucel], and of the patients who have a response, half of them were alive at the 4-year follow-up.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F6b7c9a3270c71a70749ba86000cfc78a29d74309-2988x1702.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=30 "A third of patients had a response [to lifileucel], and of the patients who have a response, half of them were alive at the 4-year follow-up.")
![We have the current CAR [T-cell therapies], which target CD19; however, we need others.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F6d5ddb2c2098f525a65b378ece6ca55a114f95fc-2974x1660.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=30 "We have the current CAR [T-cell therapies], which target CD19; however, we need others.")
Navigating AE Management for Cellular Therapy Across Hematologic Cancers
A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.
GLP-1 Receptor Agonist Use and Weight Change in Patients With Breast Cancer
Patients with breast cancer experience significant weight loss after using GLP-1 receptor agonists, highlighting potential benefits for obesity management in this population.
